#vleadersLifeScience 2017: Meet Carlos Ciller from RetinAI Medical
17.05.2017
Leaving to Boston on June 11 until June 17, this year’s venture leaders Life Science forming the ‘Swiss National Startup Team Life Science 2017’ reflect the impressive quality of Swiss startups, whose innovations come from the best universities and research institutes of Switzerland. Learn more about their growth objectives before the trip in our short interview series, running from May 9 to May 23 on venturelab.ch, Facebook, Twitter and LinkedIn.
 Carlos Ciller, CEO of RetinAI
|
 |
You can see the whole campaign on twitter.com/venturelab_ch searching the hashtag #vleadersLifeScience.
RetinAI Medical is focused on empowering eye care professionals and doctors using artificial intelligence. RetinAI uses the latest machine learning techniques (deep learning) and medical image processing to reach human-level performance for the assisted automatic evaluation of Optical Coherence Tomography (OCT), Fundus Image Photography and retinal Angiography. These techniques can be applied to the early detection and screening of the following pathologies: Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Glaucoma, and a multitude of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
Why do you choose Boston as your business development destination?
Boston is one of the most important hubs in the world for Life Science, with a perfect tandem between high quality hospitals, universities and companies in the field, it is among the best entry points to the US market together with San Francisco. We believe that the future of our company is going to be driven strongly by the experiences and feedback that we will receive from industry professionals and successful entrepreneurs in the area.
What do you want to achieve from the trip?
We have two different goals. On one side, we want to receive feedback from entrepreneurs and industry leaders who have been involved in creating companies in the US, to understand North American company dynamics. On the other side, we want to expand our network and pave the ground for starting a collaboration with major hospitals and clinical research organizations in the Boston area.
Why is venture leaders Life Science really beneficial for your company?
The results of this trip could open one of the most important markets for medical healthcare of the eye. Furthermore, it would allow us to get a glimpse of the savoir-faire within the US market, an experience that most easily comes together with time and dedication in the target location. The learning process you are offered when you discuss with proficient entrepreneurs accelerates your learning curve. We believe that the venture leaders program provides a unique opportunity to challenge your idea and your market, and we are willing to undergo this stress test!